Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment

Código QR

Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment

Narongrit Kasemsap,1 Satrirat Onsanit,2 Piyawan Chiewthanakul,3 Kannikar Kongbunkiat,1 Chonthicha Tanking,1 Nisa Vorasoot,1 Kittisak Sawanyawisuth,1,4 Somsak Tiamkao1,5 1Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 2Department of Medicine, Udonthani Hospital, Udonth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kasemsap N, Onsanit S, Chiewthanakul P, Kongbunkiat K, Tanking C, Vorasoot N, Sawanyawisuth K, Tiamkao S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Parkinson’s disease original generic levodopa efficacy motor complication Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1327f5ff3ec74af9b9aa276c0d383a7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006)

Comparación farmacocinética de Sinemetây Grifoparkinâ (levodopa/carbidopa 250/25 mg) en pacientes con enfermedad de Parkinson avanzada: un estudio con dosis única
por: Chaná C,Pedro, et al.
Publicado: (2003)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
por: Szász JA, et al.
Publicado: (2019)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: José-Francisco Rocha, et al.
Publicado: (2021)

Síndrome neuroléptico maligno-like como complicación en enfermedad de Parkinson: Desenlace fatal. Reporte de un caso y revisión de la literatura
por: Salinas S,Carlos, et al.
Publicado: (2014)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu N, et al.
Publicado: (2018)

Impact of intravenous thrombolysis on length of hospital stay in cases of acute ischemic stroke
por: Kasemsap N, et al.
Publicado: (2018)

Consideraciones sobre las complicaciones motoras y neurotoxicidad de la levodopa en la enfermedad de Parkinson
por: Venegas F.,Pablo
Publicado: (2005)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
por: A Ahmadi Ahangar, et al.
Publicado: (2002)

Relationships between Freezing of Gait Severity and Cognitive Deficits in Parkinson’s Disease
por: Jamie L. Scholl, et al.
Publicado: (2021)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin VA, et al.
Publicado: (2020)

Journal of generic medicines
Publicado: (2003)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
por: Szász JA, et al.
Publicado: (2019)

Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
por: Hirofumi Matsuyama, et al.
Publicado: (2021)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel AB, et al.
Publicado: (2018)

Parkinson's disease

GENERICITY AND THE INTERPRETATION OF THE COPULAS BY SPANISH-SPEAKING CHILDREN
por: HOLTHEUER BEAUSIRE,CAROLINA, et al.
Publicado: (2015)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser RA, et al.
Publicado: (2018)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno N, et al.
Publicado: (2020)

DEVELOPMENT OF A MODIFIED CARBON ELECTRODE WITH IONIC LIQUID AND ITS APPLICATION FOR ELECTROCATALYTIC OXIDATION AND VOLTAMMETRIC DETERMINATION OF LEVODOPA
por: MONCADA,V, et al.
Publicado: (2014)

Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease
por: Ezgi Saylam, et al.
Publicado: (2021)

SOME ASPECTS OF EFFECTIVENESS AND SAFETY OF ANTIBACTERIAL DRUGS IN PREGNANCY
por: D. Y. Zhukova, et al.
Publicado: (2012)

Generic Extensions in Contemporary British Poetry
por: Peter Hühn
Publicado: (2021)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Yi Wu, et al.
Publicado: (2021)

Journal of Parkinson's disease

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
por: Cao,Xuebing, et al.
Publicado: (2016)

Psychosocial therapy for Parkinson's-related dementia: intervention development
por: McCormick SA, et al.
Publicado: (2017)

Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors
por: Wang Q, et al.
Publicado: (2014)

Factors associated with poor discharge status in patients with status epilepticus at Khon Kaen hospital
por: Chiewthanakul P, et al.
Publicado: (2015)

Electrocatalytic determination of levodopa in presence of cabergoline using carbon paste electrode modified with graphene quantum dots/2-chlorobenzoyl ferrocene/ionic liquid
por: Peyman Mohammadzadeh Jahani
Publicado: (2021)

Slurs: Semantic Content, Expressive Content and Social Generics
por: Federico Cella
Publicado: (2017)

Terapia neuroprotectora de la Enfermedad de Parkinson
por: Miranda,Marcelo, et al.
Publicado: (2004)

A posturographic procedure assessing balance disorders in Parkinson's disease: a systematic review
por: Kamieniarz A, et al.
Publicado: (2018)

Pharmacological methods of therapy in Parkinson’s disease
por: Y. N. Bykov, et al.
Publicado: (2016)

Ethical Acceptability of Using Generic Consent for Secondary Use of Data and Biological Samples in Medical Research
por: Frunză,Ana, et al.
Publicado: (2017)

Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics
por: Bayarsaikhan E, et al.
Publicado: (2016)